MAKINDO MEDICINEClinical textbook for medical students and doctors
For education and revision only. Not individual medical advice; check current NICE/BNF and local guidance before clinical use. Clinical safety and terms.
Chapter 53 of 268
Images
MAKINDO MEDICINE · Neurology & Stroke53 / 268

Neurology: Oncology and Hydrocephalus

🧭 This chapter brings together brain tumours and hydrocephalus. Acute spinal cord compression, meningitis and encephalitis are covered in the Neurological Emergencies chapter.
Your four questions for every patient: Is there a structural cause that needs imaging? Is this a treatable complication of a systemic disease, drug or infection? Is the problem functional - and have I made a positive diagnosis rather than just excluding things? What does the patient need to know about driving and safety?


Brain Tumours

Types:

  • Metastases - the commonest brain tumours in adults. They come from the lung (the commonest), breast, melanoma, kidney and colon. Often multiple, at the grey–white matter junction.
  • Gliomas (WHO 2021 classification uses molecular markers):
    • Glioblastoma (IDH-wildtype) - the commonest primary malignant tumour; older adults; aggressive. MRI with contrast. Glioblastoma shows ring enhancement with central necrosis and surrounding oedema.
  • Astrocytoma, IDH-mutant - younger adults; slower.
  • Oligodendroglioma (IDH-mutant, 1p/19q codeleted) - often presents with seizures; best prognosis of the gliomas; often calcified.
  • Meningioma: The commonest primary brain tumour overall - usually benign, slow-growing, arising from the meninges. Commoner in women; after radiation; in NF2. Often found by chance. Meningioma MRI with contrast shows a dural-based enhancing mass with a "dural tail"
  • Primary CNS lymphoma: Immunosuppressed people (HIV, transplant) and older adults. Deep periventricular lesions. Avoid steroids before biopsy if possible - they can make the lymphoma disappear temporarily and prevent diagnosis.
  • Others:
    • Vestibular schwannoma (acoustic neuroma) - one-sided hearing loss, tinnitus, imbalance.
    • Pituitary tumours (see the Pituitary chapter).
    • Craniopharyngioma.
    • Haemangioblastoma (VHL).
    • Children: medulloblastoma, pilocytic astrocytoma, ependymoma (posterior fossa).
  • How brain tumours present:

    • Seizures - especially low-grade gliomas and meningiomas. A new seizure in an adult always needs brain imaging.
    • Progressive focal deficit - weakness, speech or visual field loss developing over weeks.
    • Cognitive or personality change (frontal tumours) - can be mistaken for depression or dementia.
    • Raised intracranial pressure: Headache worse on lying down, coughing and in the morning. Vomiting. Papilloedema. Sixth nerve palsy. Drowsiness.
    • Headache alone is an uncommon presentation.

    Referral (NICE NG12): Adults with progressive, subacute loss of central neurological function should have an urgent direct-access MRI (or CT) or suspected cancer referral.

    ↑ Back to index

    Managing Brain Tumours
    • Imaging: MRI with contrast. Glioblastoma shows ring enhancement with central necrosis and surrounding oedema; meningioma shows a dural-based enhancing mass with a "dural tail".
    • Differential diagnosis of a ring-enhancing lesion:
      • Glioblastoma.
      • Metastasis.
      • Abscess.
      • Toxoplasmosis (HIV).
      • Lymphoma.
      • Tumefactive demyelination.
      • Radiation necrosis.
    • Symptom control:
      • Dexamethasone for symptomatic brain swelling (e.g. 8–16 mg daily, then reduce to the lowest effective dose). Give a PPI, monitor glucose, and watch for steroid myopathy, infection and mood change. Give in the morning.
      • Seizures: Levetiracetam (few interactions with chemotherapy). No routine prevention without seizures.
      • VTE is common - prophylaxis and treatment as appropriate.
    • Glioblastoma (NICE NG99):
      • Maximal safe surgical resection, then radiotherapy with temozolomide, then 6 cycles of temozolomide.
      • MGMT promoter methylation predicts better response to temozolomide.
      • Median survival about 12–18 months.
      • Shorter radiotherapy courses for older or frailer patients.
    • Lower-grade gliomas: Surgery, radiotherapy and chemotherapy (PCV or temozolomide). IDH inhibitors (e.g. vorasidenib) are a newer option for some IDH-mutant tumours.
    • Meningioma: Watch-and-scan if small and without symptoms; surgery or stereotactic radiosurgery if growing or symptomatic.
    • Brain metastases:
      • Stereotactic radiosurgery for a limited number of lesions; surgery for a single large lesion.
      • Systemic therapies that cross into the brain (e.g. targeted drugs in lung cancer and melanoma).
      • Whole-brain radiotherapy is now used less often.
      • Best supportive care for poor performance status.
    • Holistic care:
      • Clinical nurse specialist.
      • Rehabilitation.
      • Cognitive and mood support.
      • Driving (DVLA rules depend on tumour type and treatment).
      • Early palliative care and advance care planning.

    ↑ Back to index

    Paraneoplastic Neurological Syndromes

    What they are: Immune attacks on the nervous system triggered by a cancer elsewhere. They often appear before the cancer is found, develop over weeks, and can be very disabling.

    SyndromeTypical antibody and cancer
    Lambert–Eaton syndromeVGCC - small cell lung cancer
    Subacute cerebellar degenerationAnti-Yo (ovary, breast); anti-Tr (Hodgkin lymphoma); anti-Hu
    Limbic encephalitisAnti-Hu (small cell lung cancer); anti-Ma2 (testicular cancer); anti-AMPA, GABA-B
    Sensory neuronopathyAnti-Hu - small cell lung cancer
    Opsoclonus–myoclonusAnti-Ri (breast); neuroblastoma in children
    Stiff person syndromeAnti-amphiphysin (breast); anti-GAD (usually not paraneoplastic - associated with type 1 diabetes)
    Anti-NMDA receptor encephalitisOvarian teratoma
    • Search for the cancer: CT chest, abdomen and pelvis; PET-CT; mammography, testicular or pelvic ultrasound as relevant. Repeat for up to 2–4 years if negative.
    • Treatment: Treat the cancer - the most important step. Add immunotherapy (steroids, IVIg, plasma exchange, rituximab); syndromes with antibodies to intracellular targets (Hu, Yo) respond poorly.

    ↑ Back to index

    Hydrocephalus and Normal Pressure Hydrocephalus
    • Hydrocephalus: Enlarged ventricles from blocked or poorly absorbed CSF.
      • Obstructive (non-communicating) - tumour, aqueduct stenosis, colloid cyst, posterior fossa haemorrhage.
      • Communicating - after subarachnoid haemorrhage, meningitis or head injury (absorption blocked).
      • Acute hydrocephalus causes headache, vomiting, drowsiness and upgaze palsy - neurosurgical emergency (external ventricular drain).
    • Normal pressure hydrocephalus (NPH):
      • Older adults; often idiopathic, or after SAH, meningitis or head injury.
      • Classic triad:
        • Gait disturbance first - broad-based, shuffling, "magnetic" gait with difficulty turning.
        • Urinary urgency and incontinence.
        • Cognitive slowing (frontal-subcortical).
      • Imaging: Enlarged ventricles out of proportion to atrophy (Evans index over 0.3), with tight high-convexity sulci.
      • Tap test: Remove 30–50 mL of CSF by LP and re-test gait, or use a lumbar drain for several days. Improvement predicts benefit from a shunt.
      • Treatment: Ventriculoperitoneal shunt. Gait responds best; cognition responds least.
      • Mimics: vascular parkinsonism, Parkinson's disease, cervical myelopathy, Alzheimer's disease.
    • Shunt problems:
      • Blockage - headache, vomiting, drowsiness (raised pressure) - urgent neurosurgical review.
      • Infection - often within months of surgery (staphylococci).
      • Over-drainage - low-pressure headache, subdural collections.
    Drug Reference Table
    DrugKey points
    Dexamethasone
    e.g. 8–16 mg daily, then reduce
    Brain tumour oedema; give with a PPI; check glucose; avoid before biopsy if lymphoma is suspected.
    LevetiracetamSeizures with brain tumours; few interactions.
    TemozolomideGlioblastoma with radiotherapy; myelosuppression; better response if MGMT is methylated.

    ↑ Back to index

    Spot the Diagnosis
    ClueDiagnosis
    Ring-enhancing lesion with central necrosis and oedema in a 68-year-oldGlioblastoma (or metastasis)
    Dural-based enhancing mass with a dural tailMeningioma
    Deep periventricular lesion that shrank after steroids in a transplant recipientPrimary CNS lymphoma
    Rapid unsteadiness in a woman, anti-Yo antibodiesParaneoplastic cerebellar degeneration (ovarian or breast cancer)
    Shuffling magnetic gait, incontinence and slowed thinking, big ventriclesNormal pressure hydrocephalus

    ↑ Back to index

    Exam-style Scenarios

    1. A 62-year-old has had 6 weeks of worsening left arm weakness and personality change. MRI shows a right frontal ring-enhancing mass with oedema.
    Answer: Likely glioblastoma (or metastasis).

    • Dexamethasone with a PPI; glucose checks.
    • CT chest, abdomen and pelvis to look for a primary.
    • Neuro-oncology MDT: maximal safe resection, then radiotherapy with temozolomide.
    • Seizure plan; DVLA advice; specialist nurse and palliative care.

    2. A 75-year-old has 1 year of a shuffling gait, then urinary urgency and slowed thinking. CT shows enlarged ventricles.
    Answer: Suspected normal pressure hydrocephalus.

    • CSF tap test (or lumbar drain) with gait assessment before and after.
    • Refer to neurosurgery for a VP shunt if he improves.

    ↑ Back to index

    Key Points
    • Metastases are the commonest brain tumours; glioblastoma is the commonest primary malignant one; meningioma is the commonest primary overall.
    • A new seizure or a progressive focal deficit in an adult needs brain imaging.
    • Dexamethasone for tumour oedema (with PPI and glucose checks); avoid steroids before biopsy if lymphoma is likely.
    • Glioblastoma: surgery, radiotherapy and temozolomide; MGMT methylation predicts response.
    • Paraneoplastic syndromes often come before the cancer - search with CT and PET.
    • NPH: gait, incontinence, cognition - tap test, then shunt.

    ↑ Back to index

    Guidelines and Further Reading
    • NICE NG99: Brain tumours (primary) and brain metastases in over 16s
    • NICE NG12: Suspected cancer - recognition and referral
    • WHO Classification of Tumours of the Central Nervous System (2021)

    ↑ Back to index

    End of chapter 53